ENTPD2 antibodies, combination therapies, and methods of using the antibodies and… Grant US-11939397-B2 United States of America 26 Mar 2024
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity Grant US-11685792-B2 United States of America 27 Jun 2023
Anti-CD39 antibody compositions and methods Grant US-11655303-B2 United States of America 23 May 2023
Compositions and methods for treating cancer Grant US-11578136-B2 United States of America 14 Feb 2023
Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular… Grant US-11377503-B2 United States of America 05 Jul 2022
Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging Grant US-11287427-B2 United States of America 29 Mar 2022
ENTPD2 antibodies, combination therapies, and methods of using these antibodies and… Application CN-112218656-A China 12 Jan 2021
ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY Grant EP-3153526-B1 European Patent Office 23 Sep 2020
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity Grant US-10662253-B2 United States of America 26 May 2020
ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND… Application WO-2019229658-A1 World Intellectual Property Organisation (WIPO) 05 Dec 2019
P2X7 ANTAGONISTS AS FRONTLINE OR ADJUNCTIVE TREATMENT AGAINST STATUS EPILEPTICUS Application WO-2013087943-A1 World Intellectual Property Organisation (WIPO) 20 Jun 2013
P2x7 antagonists as frontline or adjunctive treatment against status epilepticus Application EP-2604265-A1 European Patent Office 19 Jun 2013